Clinical trials: Shock
Sepsis, Severe Sepsis
Protocolized Care for Early Septic Shock
The ProCESS study is large, 5-year, multicenter study of alternative resuscitation strategies for septic shock. The study hypothesizes that there are "golden hours" in the initial management of septic shock where prompt…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- ProCESS (NCT00510835)
- Testing
- Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
- Where
- 31 sites in United States
- Volunteers
- 1,351 people
- Sponsor
- University of Pittsburgh
Sepsis, Disease Progression
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
To investigate the role of initial venous lactate in predicting the severity progression to overt septic shock and 30-day mortality in non-elderly patients without hemodynamic shock who suspected to have acute infections.
- Conditions
- Sepsis, Disease Progression, Septic Shock, Fatal Outcome
- Trial name
- NCT01947127
- Where
- Thailand
- Volunteers
- 458 people
- Sponsor
- Chulalongkorn University
Shock
Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)
The short term goal of this study is to evaluate a non-invasive approach that optimizes intravenous (IV) fluid administration according to heart performance and results in surrogate improvements in morbidity and mortality via…
- Trial name
- EFFORT (NCT01128413)
- Testing
- Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Septic Shock
PK Analysis of Piperacillin in Septic Shock Patients
Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02306928
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University of Aarhus
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Blunt Trauma, Penetrating Wound
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
Primary Aim: To determine the feasibility and safety of hypotensive resuscitation for the early treatment of patients with traumatic shock compared to standard fluid resuscitation.
- Conditions
- Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
- Trial name
- HypoResus (NCT01411852)
- Testing
- 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
- Where
- 6 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- University of Washington
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Severe Sepsis, Septic Shock
Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock
Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality.
- Trial name
- MiCHO (NCT00535821)
- Testing
- Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Loma Linda University
Hemorrhagic Shock
Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy
Overall aim of this work is to evaluate new methods of resuscitation that can be applied by front-line responders on the battlefield, in civilian life, or which can be used during initial resuscitation in the first fixed facility…
- Trial name
- NCT01239680
- Testing
- Glutamine, Ringer's Lactate
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Missouri, Kansas City
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Sepsis
Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
- Trial name
- NCT00608322
- Testing
- Inhaled nitric oxide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Institute of General Medical Sciences (NIGMS)
Hypovolemic Shock, Hemorrhage
Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt
This study will test the efficacy of the NASG on women suffering from obstetric hemorrhage as compared to hemorrhaging women who do not receive the NASG.
- Trial name
- NCT00305253
- Testing
- Non-pneumatic Anti-shock Garment (NASG)
- Where
- 2 sites in Egypt
- Volunteers
- 990 people
- Sponsor
- University of California, San Francisco
Sepsis
Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure
The purpose of this study is to determine the effect of resatorvid on subjects with sepsis.
- Trial name
- NCT00633477
- Testing
- Resatorvid
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Takeda
Sepsis
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients…
- Trial name
- NCT00604214
- Testing
- Drotrecogin alfa (activated)
- Where
- 150 sites in United States, Australia and 16 more
- Volunteers
- 1,696 people
- Sponsor
- Eli Lilly and Company
Shock, Traumatic
Hypertonic Resuscitation Following Traumatic Injury
The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock.
- Trial name
- NCT00316017
- Testing
- 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline
- Where
- 10 sites in United States, Canada
- Volunteers
- 895 people
- Sponsor
- University of Washington
Sepsis, Septic Shock
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving…
- Trial name
- NCT00279214
- Testing
- drotrecogin alfa (activated)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company